Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Papp

Showing results (281-290 of 461) with videos related to

Pageof 47
Sort By:
Archives of General Psychiatry|March 7, 1998
Plasma cortisol concentrations preceding lactate-induced panic. Psychological, biochemical, and physiological correlatesJ D Coplan, R Goetz, D F Klein, et al.
Journal of the American Academy of Dermatology|June 1, 2020
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension studyAndrew Blauvelt, Kim A Papp, Joseph F Merola, et al.
The American Journal of Psychiatry|January 20, 1998
Pretreatment attrition in a comparative treatment outcome study on panic disorderS G Hofmann, D H Barlow, L A Papp, et al.
The British Journal of Dermatology|April 27, 2012
A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasisA B Gottlieb, R G Langley, B E Strober, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|March 24, 1999
Plasma anti-serotonin and serotonin anti-idiotypic antibodies are elevated in panic disorderJ D Coplan, H Tamir, D Calaprice, et al.
Dermatology and Therapy|July 14, 2026
Pushing the Boundaries of Topical Therapy in Patients with Atopic Dermatitis: A Review of Baseline Disease Severity and Burden in Clinical TrialsMelinda J Gooderham, H Chih-Ho Hong, Charles Lynde, et al.
The British Journal of Dermatology|February 15, 2017
Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumabJ Bagel, S Tyring, K C Rice, et al.
The Journal of Clinical Psychiatry|December 1, 1990
The pharmacotherapy of moral or religious scrupulosityB A Fallon, M R Liebowitz, E Hollander, et al.
American Journal of Clinical Dermatology|March 31, 2018
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
American Journal of Clinical Dermatology|January 12, 2017
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Pageof 47

Showing results (281-290 of 461) with videos related to

Sort By:
Pageof 47
Archives of General Psychiatry|March 7, 1998
Plasma cortisol concentrations preceding lactate-induced panic. Psychological, biochemical, and physiological correlatesJ D Coplan, R Goetz, D F Klein, et al.
Journal of the American Academy of Dermatology|June 1, 2020
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension studyAndrew Blauvelt, Kim A Papp, Joseph F Merola, et al.
The American Journal of Psychiatry|January 20, 1998
Pretreatment attrition in a comparative treatment outcome study on panic disorderS G Hofmann, D H Barlow, L A Papp, et al.
The British Journal of Dermatology|April 27, 2012
A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasisA B Gottlieb, R G Langley, B E Strober, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|March 24, 1999
Plasma anti-serotonin and serotonin anti-idiotypic antibodies are elevated in panic disorderJ D Coplan, H Tamir, D Calaprice, et al.
Dermatology and Therapy|July 14, 2026
Pushing the Boundaries of Topical Therapy in Patients with Atopic Dermatitis: A Review of Baseline Disease Severity and Burden in Clinical TrialsMelinda J Gooderham, H Chih-Ho Hong, Charles Lynde, et al.
The British Journal of Dermatology|February 15, 2017
Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumabJ Bagel, S Tyring, K C Rice, et al.
The Journal of Clinical Psychiatry|December 1, 1990
The pharmacotherapy of moral or religious scrupulosityB A Fallon, M R Liebowitz, E Hollander, et al.
American Journal of Clinical Dermatology|March 31, 2018
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
American Journal of Clinical Dermatology|January 12, 2017
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Pageof 47